Atossa Genetics Incorporated (NASDAQ:ATOS) Sellers Increased By 7.32% Their Shorts

The stock of Atossa Genetics Incorporated (NASDAQ:ATOS) registered an increase of 7.32% in short interest. ATOS’s total short interest was 297,800 shares in April as published by FINRA. Its up 7.32% from 277,500 shares, reported previously. With 565,800 shares average volume, it will take short sellers 1 days to cover their ATOS’s short positions. The short interest to Atossa Genetics Incorporated’s float is 1.16%. The stock is up 0.29% or $0.001 after the news, hitting $0.345 per share. About 73,980 shares traded hands. Atossa Genetics Inc (NASDAQ:ATOS) has declined 57.50% since August 25, 2015 and is downtrending. It has underperformed by 67.79% the S&P500.

Atossa Genetics Inc. is a healthcare company. The company has a market cap of $11.24 million. The Firm is engaged in the development of laboratory services, medical devices and therapeutics. It currently has negative earnings. The Company’s laboratory services are being developed and performed by its wholly owned subsidiary, the National Reference Laboratory for Breast Health, Inc. .

The institutional sentiment decreased to 0.57 in 2015 Q3. Its down 1.93, from 2.5 in 2015Q2. The ratio is negative, as 5 funds sold all Atossa Genetics Inc shares owned while 2 reduced positions. 2 funds bought stakes while 2 increased positions. They now own 5.59 million shares or 447.02% more from 1.02 million shares in 2015Q2.

Concert Wealth Management Inc. holds 0.01% of its portfolio in Atossa Genetics Inc for 71,942 shares. Vanguard Group Inc owns 5.14 million shares or 0.01% of their US portfolio. Moreover, Blackrock Fund Advisors has 0% invested in the company for 60,656 shares. The California-based Blackrock Institutional Trust Company N.A. has invested 0% in the stock. Blackrock Investment Management Llc, a New Jersey-based fund reported 3,682 shares.

Atossa Genetics Inc - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.

Add Comment